| *Meeting Summary: Global Vaccine and Immunization Research Forum, 2021 | Andrew Ford | | Journal article | English |
| Agenda - GVIRF 2021 | GVIRF Secretariat | 2021 | Presentation | English |
| Introduction to GVIRF | B. Fenton Hall | 2021 | Webinar | English |
| KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience | Anthony Fauci | 2021 | Webinar | English |
| KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience | Anthony Fauci | 2021 | Presentation | English |
| KN2 The Lessons of COVID-19 for Vaccine Development | Bill & Melinda Gates Foundation | 2021 | Webinar | English |
| KN2.2 Innovating from Research to Impact at Scale: the role of the Gavi Alliance | Anuradha Gupta | 2021 | Webinar | English |
| KN3 Research for Equity | Soumya Swaminathan | 2021 | Presentation | English |
| KN3 Research for Equity - VIDEO | Soumya Swaminathan | 2021 | Webinar | English |
| P1 Epidemic and Pandemic Preparedness and Response | George F. Gao, Helen Rees | | Webinar | English |
| P1.1 Research during outbreak response: from Ebola to the COVID-19 pandemic | Ana Maria Henao Restrepo | 2021 | Presentation | English |
| P1.2 Rapid Response Platforms for COVID-19 Vaccine | Melanie Saville | 2021 | Presentation | English |
| P1.3 Rapid (and precise) COVID-19 Vaccine Development Enabled by Prototype Pathogen Preparedness | Barney S. Graham | 2021 | Presentation | English |
| P2 HIV, TB & Malaria Vaccine Update | Norman Baylor, Lucky Slamet | 2021 | Webinar | English |
| P2.1 Current status and future prospects for human immunodeficiency virus (HIV) vaccines | Linda-Gail Bekker, University of Cape Town | 2021 | Presentation | English |
| P2.2 Update on progress in tuberculosis vaccine development | Ann Ginsberg | 2021 | Presentation | English |
| P3 Shaping the Future: Equitable Access for All | Daniel Feikin, Robin Nandy | | Webinar | English |
| P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030 | Katherine L. O'Brien | 2021 | Presentation | English |
| P3.2 Impact of COVID-19 on coverage and equity | Samir Sodha | 2021 | Presentation | English |
| W1 Innovations in Vaccine Manufacturing | Antu Dey, Rajat Goyal | | Webinar | English |
| W1.2 Vaccine Manufacturing at Lab Scale: A paradigm shift to more affordable vaccines | Ahd Hamidi | 2021 | Case study | English |
| W1.3 Not enough to go around: vaccine manufacturing for the COVID-19 pandemic | Casey Selwyn | | Presentation | English |
| W2 Emerging Platforms | Lynda Stuart, Kanta Subbarao, Florian Krammer, Nathalie Garcon, Sarah Gilbert, Christian Mandl | 2021 | Webinar | English |
| W2.1 Nucleic acid vaccines: Is it all done? | Christian Mandl | | Presentation | English |
| W2.2 Viral vectored vaccine platform technologies | Sarah Gilbert, University of Oxford | 2021 | Presentation | English |
| W2.3 Adjuvants | Nathalie Garcon | 2021 | Presentation | English |
| W2.4 Universal Influenza Vaccines | Kanta Subbarao | 2021 | Presentation | English |
| W3 Innovation in Vaccination | Bernhards Ogutu, David Durrheim | | Webinar | English |
| W3.2 Transformative Concepts for Mass Vaccination and Pandemic Response | Matthew Downham, CEPI | 2021 | Presentation | English |
| W3.3 Considerations for mass deployment of innovative vaccines in low- and middle-income country immunization programs | Fred Were | | Presentation | English |
| W4 Controlled Human Infection Models for Vaccine Research and Development | Annie Mo, Gagandeep Kang | | Webinar | English |
| W4.1 Controlled human malaria infection — tool for accelerating vaccine development | Melissa Kapulu, KEMRI-Wellcome Trust Research Programme | 2021 | Presentation | English |
| W4.2 Typhoid controlled human infection model | Andrew Pollard | 2021 | Presentation | English |
| W5 New and Improved Vaccines on the Horizon | Kathleen Neuzil | | Webinar | English |
| W5.1 Salmonella typhi vaccines, development and deployment | Sushant Sahastrabuddhe, International Vaccine Institute | 2021 | Presentation | English |
| W5.2 Schistosomiasis vaccines, development and role in elimination | Robert Bergquist, Geospatial Health | 2021 | Presentation | English |
| W5.3 Single-dose HPV Vaccination | Aimee R. Kreimer | 2021 | Presentation | English |
| W5.4 Improved vaccines: Novel oral polio vaccine (OPV) | Ananda S. Bandyopadhyay | 2021 | Presentation | English |
| W6 Vaccine Development to Access | Alejandro Cravioto, Birgitte Giersing, David Kaslow, Deepali Pate, Ian Hudson, Joshua Chu, Narendra Arora, Rino Rappuoli, Sai Prasad | 2021 | Webinar | English |
| W6.1 Vaccine Development to Access: Opportunities, risks and potential valleys of death | David Kaslow | 2021 | Presentation | English |
| W6.2 Vaccine development to access: Is there a role for earlier policy consideration? | Rino Rappuoli, GSK Vaccines | 2021 | Presentation | English |
| W6.3 Building the concept of WHO Vaccine Preferred Policy Profiles | Birgitte Giersing | 2021 | Presentation | English |
| W7.1 Protection of newborn infants through vaccination | Tobias Kollmann | | Presentation | English |
| W8 Prioritization for Vaccine R&D | Peter Hotez, Jerome Kim, B. T. Slingsby | 2021 | Webinar | English |
| W8.1 Decision-making and prioritization of vaccines to address public health needs in LMICs | Bill Hausdorff | | Presentation | English |
| W8.2 Prioritization of Vaccines for Global Health | Jerome Kim | 2021 | Presentation | English |
| W8.3 The State of Play: Industry vaccine trends from the Access to Medicine Index | Margo Warren, Access to Medicine Foundation | 2021 | Presentation | English |
| W9 Building and Sustaining Uptake | Lisa Menning | 2021 | Case study | English |
| W9.1 Building and Sustaining Uptake: Summary of the latest evidence and open research questions | Julie Leask | 2021 | Presentation | English |
| W9.2 Evidence and Lessons Learned on Social Sciences Analytics around Vaccination | Simone Carter | 2021 | Case study | English |
